DRC

DRC Medicine Ltd. is a Japanese biotechnology and healthcare company founded in 2007, specializing in advanced medical technologies for global health challenges. The company is primarily recognized for its proprietary Hydro Silver Titanium® technology, a photocatalytic compound used in therapeutic masks for seasonal allergic rhinitis and consumer hygiene products. DRC is also advancing a pipeline of AI-powered In Vitro Diagnostic (IVD) kits for infectious diseases and allergens, utilizing its unique cell-free protein synthesis platform. Furthermore, the company is expanding into drug development through the acquisition of an innovative ATP-enhancing drug candidate for Parkinson's disease, which is currently in clinical trials. In 2025, DRC entered into a business combination agreement with Ribbon Acquisition Corp to become a publicly traded company on the Nasdaq.